Sacubitril/Valsartan (Entresto): A Comprehensive Clinical and Pharmacological Monograph

Section 1: Pharmacological Profile and Mechanism of Action

1.1. Introduction to Angiotensin Receptor-Neprilysin Inhibition (ARNI)

Sacubitril/valsartan represents a seminal advancement in cardiovascular pharmacotherapy, establishing a novel therapeutic class known as Angiotensin Receptor-Neprilysin Inhibitors (ARNIs).[1] Marketed under the brand names Entresto and Entresto Sprinkle, it is a first-in-class agent formulated as a fixed-dose, supramolecular sodium salt complex containing two active moieties: the neprilysin inhibitor prodrug sacubitril and the angiotensin II receptor blocker (ARB) valsartan.[1] One complex of sacubitril/valsartan consists of six sacubitril anions, six valsartan dianions, 18 sodium cations, and 15 water molecules, yielding the molecular formula

C288​H330​N36​Na18​O48​⋅15H2​O.[2]

The development of the ARNI class was a direct and deliberate response to the limitations of prior attempts at neurohormonal modulation in heart failure. Specifically, the experience with omapatrilat, a vasopeptidase inhibitor that combined neprilysin inhibition with angiotensin-converting enzyme (ACE) inhibition, provided a critical lesson. While effective at lowering blood pressure, omapatrilat was associated with a prohibitively high incidence of angioedema.[4] This adverse effect was traced to the dual inhibition of two key enzymes responsible for bradykinin degradation: ACE and neprilysin.[2] The resulting excessive accumulation of bradykinin led to increased vascular permeability and angioedema. The ARNI class was intelligently designed to circumvent this issue by pairing the neprilysin inhibitor with an ARB instead of an ACE inhibitor. This strategic combination allows for potent blockade of the renin-angiotensin-aldosterone system (RAAS) without interfering with bradykinin metabolism to the same extent, thereby achieving a more favorable safety profile while delivering robust therapeutic efficacy.[6]

1.2. The Dual-Action Mechanism: Synergistic Neurohormonal Modulation

The pathophysiology of heart failure (HF) is characterized by a profound imbalance between two opposing neurohormonal systems. On one side, the RAAS and the sympathetic nervous system are chronically over-activated, driving vasoconstriction, sodium and water retention, and maladaptive cardiac remodeling (fibrosis and hypertrophy).[3] On the other side, the endogenous natriuretic peptide (NP) system, a compensatory mechanism that promotes vasodilation and natriuresis, is activated but ultimately overwhelmed and insufficient to counteract the deleterious effects of the RAAS.[8] The therapeutic strategy of sacubitril/valsartan is to simultaneously address both sides of this imbalance: augmenting the protective NP system while suppressing the harmful RAAS.[9]

1.2.1. Sacubitril: Neprilysin Inhibition and Enhancement of the Natriuretic Peptide System

Sacubitril is an inactive prodrug that undergoes rapid metabolic activation via de-ethylation by esterases to its active metabolite, LBQ657.[2] LBQ657 is a potent inhibitor of neprilysin (also known as neutral endopeptidase), a zinc-dependent membrane metallopeptidase that is ubiquitously expressed.[3] Neprilysin is the primary enzyme responsible for the degradation of a host of vasoactive peptides, most notably the natriuretic peptides—atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).[2] Other substrates for neprilysin include bradykinin, adrenomedullin, substance P, and angiotensin I and II.[3]

By inhibiting neprilysin, LBQ657 prevents the breakdown of these peptides, leading to a significant increase in their circulating concentrations and enhancing their physiological effects.[12] The elevated levels of NPs bind to their cognate receptors, resulting in a cascade of beneficial cardiovascular and renal effects. These include potent vasodilation, which reduces both cardiac preload and afterload; natriuresis (excretion of sodium) and diuresis, which reduce blood volume and congestion; and suppression of renin and aldosterone release, which further blunts the RAAS.[1] Furthermore, NPs exert direct antihypertrophic and antifibrotic effects on the myocardium, helping to attenuate or reverse adverse cardiac remodeling.[14]

1.2.2. Valsartan: Angiotensin II Receptor Blockade and RAAS Suppression

The inclusion of valsartan is not merely additive; it is essential for the efficacy and safety of the combination. Neprilysin, as noted, also degrades angiotensin II.[3] Consequently, inhibition of neprilysin by sacubitril alone would lead to a paradoxical and potentially harmful increase in circulating angiotensin II levels, which could counteract the benefits of NP enhancement and accelerate HF progression.[3]

Valsartan addresses this by acting as a highly selective antagonist of the angiotensin II type 1 (AT1) receptor.[2] By blocking this receptor, valsartan prevents angiotensin II from exerting its potent pathological effects, which include systemic vasoconstriction, stimulation of aldosterone secretion from the adrenal glands, and direct promotion of cardiac fibrosis and myocyte hypertrophy.[2] This concurrent blockade of the AT1 receptor effectively neutralizes the increased angiotensin II resulting from neprilysin inhibition, ensuring that the net effect of the drug is a shift toward the favorable actions of the augmented NP system.[6] The result is a comprehensive neurohormonal modulation that reduces vascular resistance, lowers blood pressure, and decreases the workload on the failing heart.[16]

1.3. Cellular and Molecular Cardioprotective Effects

Beyond its systemic neurohormonal effects, a growing body of experimental evidence indicates that sacubitril/valsartan exerts direct cardioprotective effects at the cellular and molecular levels. These pleiotropic actions contribute significantly to its overall therapeutic benefit in attenuating adverse cardiac remodeling.[3]

• Oxidative Stress Reduction: In preclinical models of myocardial infarction (MI) and cardiorenal syndrome, sacubitril/valsartan has been shown to mitigate oxidative stress. It achieves this by inhibiting the degradation of key antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), and by downregulating the production of reactive oxygen species (ROS) via pathways involving NADPH oxidase 4 (NOX-4) and nuclear factor E2-related factor 2 (Nrf2).[3] This reduction in oxidative burden helps preserve cardiomyocyte integrity and reduce infarct size.
• Anti-inflammatory Action: The medication demonstrates potent anti-inflammatory properties. In models of atherosclerosis and endothelial dysfunction, sacubitril/valsartan downregulates the expression of pro-inflammatory cytokines and chemokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and monocyte chemoattractant protein-1 (MCP-1). It appears to mediate these effects by inhibiting key inflammatory signaling pathways, such as the Toll-like receptor 4 (TLR4)/MyD88/NF-κB pathway and the TAK1/JNK pathway.[3] In patients with HFrEF, treatment has been shown to reduce circulating inflammatory markers and improve peripheral vascular function.[3]
• Anti-apoptotic Effects: Sacubitril/valsartan has been shown to protect against programmed cell death (apoptosis) in both cardiomyocytes and endothelial cells. It inhibits apoptosis induced by various stressors, including oxidized LDL, doxorubicin, and diabetic conditions. The underlying mechanisms involve the modulation of multiple signaling pathways, including inhibition of the TLR4/NF-κB pathway, protection of mitochondrial integrity through regulation of mitofusin 2 (Mfn2) and Drp1, and attenuation of endoplasmic reticulum (ER) stress by downregulating proteins like GRP78 and CHOP.[3]
• Attenuation of Cardiac Hypertrophy and Fibrosis: The drug directly counteracts the structural changes of adverse cardiac remodeling. In various animal models of HF, sacubitril/valsartan significantly reduces cardiomyocyte hypertrophy, as evidenced by decreased cell size and downregulation of genetic markers like ANP and β-myosin heavy chain (β-MHC).[3] It also potently inhibits cardiac fibrosis by suppressing the transforming growth factor β1 (TGF-β1)/Smad3 pathway, inhibiting the conversion of fibroblasts to myofibroblasts, and downregulating the expression of fibrotic genes such as those for collagen and fibronectin.[3]

1.4. Pharmacokinetics and Metabolism

Sacubitril/valsartan is administered orally and can be taken with or without food, as food does not have a clinically meaningful impact on systemic exposure.[12] Following oral administration, sacubitril is rapidly absorbed and converted by esterases to its active metabolite, LBQ657. Peak plasma concentrations (

Cmax​) of sacubitril are reached in approximately 0.5 hours, while the Cmax​ of LBQ657 is reached in about 2 hours.[12] The oral bioavailability of sacubitril when delivered as Entresto is estimated to be 60% or more.[12]

A critical pharmacokinetic feature is that the valsartan component in the sacubitril/valsartan co-crystal complex has a higher bioavailability than valsartan formulated in other commercially available tablets.[1] This has important dosing implications; for instance, the 26 mg, 51 mg, and 103 mg doses of valsartan in Entresto are equivalent to 40 mg, 80 mg, and 160 mg doses of valsartan in other products, respectively.[1] Both sacubitril and its active metabolite LBQ657, as well as valsartan, are highly bound to plasma proteins (approximately 94-97%).[12]

The theoretical concern that neprilysin inhibition might impair the clearance of amyloid-beta protein from the cerebrospinal fluid, a process implicated in the pathogenesis of Alzheimer's disease, has been a subject of investigation.[2] Studies have shown that sacubitril/valsartan administration can increase levels of a specific amyloid-beta fragment (Aβ1-38) in healthy subjects.[2] While this raises a potential long-term risk, a dedicated analysis within the PARAGON-HF trial found no difference in cognitive function, as measured by the Mini-Mental State Examination, between the sacubitril/valsartan and valsartan groups over a median of 3 years.[19] Nevertheless, this remains an area of ongoing scientific interest and post-marketing surveillance.

Section 2: Landmark Clinical Evidence: Heart Failure with Reduced Ejection Fraction (HFrEF)

The establishment of sacubitril/valsartan as a cornerstone therapy for heart failure with reduced ejection fraction (HFrEF) is overwhelmingly supported by the results of the PARADIGM-HF trial, a study whose findings have fundamentally altered clinical practice.

2.1. The PARADIGM-HF Trial: A Paradigm Shift in HFrEF Management

The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial was a multinational, randomized, double-blind study designed to test the hypothesis that sacubitril/valsartan was superior to the long-established standard of care, the ACE inhibitor enalapril.[7] The trial enrolled 8,442 patients with chronic, symptomatic (New York Heart Association Class II–IV) HFrEF, defined by a left ventricular ejection fraction (LVEF) of ≤40% (later amended to ≤35%).[14] All patients were required to be on stable, evidence-based doses of an ACE inhibitor or ARB and a beta-blocker prior to enrollment.[7]

Patients were randomized to receive either sacubitril/valsartan at a target dose of 97/103 mg twice daily or enalapril at a target dose of 10 mg twice daily, in addition to other standard HF therapies.[7] The trial was terminated early, after a median follow-up of 27 months, by the independent data monitoring committee due to a prespecified boundary for overwhelming benefit being crossed in the sacubitril/valsartan arm.[4]

The results were unequivocally positive and clinically transformative. Sacubitril/valsartan demonstrated profound superiority over enalapril across all major endpoints. The primary composite outcome of death from cardiovascular (CV) causes or first hospitalization for HF was significantly reduced by 20% in the sacubitril/valsartan group compared to the enalapril group. This benefit was robust and highly statistically significant, as detailed in Table 1.

Table 1: Summary of Primary and Key Secondary Outcomes in PARADIGM-HF (Sacubitril/Valsartan vs. Enalapril)

Outcome	Sacubitril/Valsartan Group (n=4,187)	Enalapril Group (n=4,212)	Hazard Ratio (95% CI)	p-value	Absolute Risk Reduction (ARR)	Number Needed to Treat (NNT)
Primary Composite (CV Death or HF Hospitalization)	21.8%	26.5%	0.80 (0.73−0.87)	<0.001	4.7%	21
Death from CV Causes	13.3%	16.5%	0.80 (0.71−0.89)	<0.001	3.2%	32
First Hospitalization for HF	12.8%	15.6%	0.79 (0.71−0.89)	<0.001	2.8%	36
Death from Any Cause	17.0%	19.8%	0.84 (0.76−0.93)	0.0009	2.8%	36
(Data sourced from 4)

The magnitude of these benefits was substantial. Sacubitril/valsartan reduced the risk of CV death by 20%, the risk of HF hospitalization by 21%, and the risk of all-cause mortality by 16%.[4] The benefit was observed early and was sustained throughout the trial's duration.[10] As a biomarker of therapeutic effect, sacubitril/valsartan also led to a significantly greater reduction in plasma levels of N-terminal pro-b-type natriuretic peptide (NT-proBNP), a key marker of ventricular wall stress, compared to enalapril.[12]

2.2. Analysis of Subgroups and Trial Methodology

A key strength of the PARADIGM-HF findings was the remarkable consistency of benefit across a wide range of prespecified subgroups. The superiority of sacubitril/valsartan was maintained regardless of patient age, sex, geographic region, NYHA class, renal function, LVEF, diabetic status, or background therapy, including the dose of beta-blocker or use of a mineralocorticoid receptor antagonist (MRA).[20]

However, a critical aspect of the trial's methodology that warrants consideration is its use of a sequential, single-blind run-in period. Before randomization, all participants entered an enalapril run-in phase, followed by a sacubitril/valsartan run-in phase.[4] Patients who experienced unacceptable side effects during either phase were excluded from randomization. This process led to the exclusion of approximately 20% of the initially screened population.[4] This trial design, while intended to ensure patient tolerance and maximize adherence, results in a "healthy cohort" effect. The randomized population was highly selected, comprising patients who were able to tolerate target or near-target doses of both drugs. This enrichment of the trial population likely contributed to the large magnitude of the observed treatment effect and the lower-than-expected rates of adverse events. While this does not invalidate the trial's conclusion of superiority, it does suggest that the magnitude of benefit and the rates of tolerability seen in the trial may be higher than what is observed in a broader, unselected "real-world" patient population. Clinicians should therefore anticipate potentially higher rates of discontinuation due to side effects like hypotension in routine clinical practice.

Furthermore, the generalizability of the results has been debated due to the demographic composition of the trial population, which was predominantly NYHA Class II (70-72%) and had low enrollment of patients from North America (7%) and of Black patients (<5%).[4]

Despite the clear superiority demonstrated in PARADIGM-HF, a persistent challenge in clinical practice is patient underdosing. Real-world registries indicate that only a small fraction of patients (e.g., 14%) on sacubitril/valsartan reach the target dose of 97/103 mg twice daily used in the trial, often limited by hypotension or renal concerns.[22] This has raised questions about the efficacy of lower doses. The PROVE-HF study provided crucial insights into this issue. It was a prospective study that treated patients with HFrEF with sacubitril/valsartan according to standard of care, with a recommended target dose of 97/103 mg twice daily. The study found that even patients maintained on low or moderate doses experienced significant and comparable improvements in cardiac remodeling (e.g., increases in LVEF, reductions in ventricular volumes) and prognostic biomarkers (e.g., NT-proBNP) over 12 months.[22] This evidence is clinically vital, as it supports the strategy of initiating and maintaining patients on any tolerated dose of sacubitril/valsartan, reinforcing that some therapy is substantially better than no therapy, even if the target dose is not achievable.

2.3. In-Hospital and Transitional Care Initiation: Insights from PIONEER-HF and TRANSITION

Initially, PARADIGM-HF provided evidence only for the use of sacubitril/valsartan in stable, chronic outpatients. This created an evidence gap and clinical uncertainty regarding the safety and efficacy of initiating the drug in patients hospitalized for acute decompensated heart failure (ADHF). The PIONEER-HF and TRANSITION trials were designed to address this gap.[24]

The PIONEER-HF trial randomized stabilized patients hospitalized with ADHF to receive either in-hospital initiation of sacubitril/valsartan or enalapril. The study demonstrated that sacubitril/valsartan led to a significantly greater reduction in NT-proBNP over 8 weeks compared to enalapril, without an increased risk of worsening renal function, hyperkalemia, or symptomatic hypotension.[21] The TRANSITION trial further supported these findings, showing that in-hospital initiation of sacubitril/valsartan (either pre- or post-discharge) was feasible and well-tolerated.[8] Together, these trials have provided the necessary evidence to support the early initiation of this life-saving therapy in the inpatient setting for appropriately stabilized patients, a strategy aimed at improving transitions of care and reducing the high risk of early post-discharge readmission.[24]

Section 3: Evolving Evidence: Heart Failure with Preserved Ejection Fraction (HFpEF)

In contrast to the clear-cut success in HFrEF, the therapeutic landscape for heart failure with preserved ejection fraction (HFpEF) has been characterized by decades of neutral clinical trials. The PARAGON-HF trial, while not meeting its primary endpoint in the overall population, provided the most significant breakthrough to date, ultimately reshaping the understanding and treatment of this heterogeneous syndrome.

3.1. The PARAGON-HF Trial: Design and Primary Outcome Analysis

Following the success of PARADIGM-HF, the Prospective comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial was designed to evaluate the efficacy and safety of sacubitril/valsartan in patients with HFpEF.[26] It was a large, randomized, double-blind, active-controlled study that enrolled 4,822 patients with symptomatic (NYHA Class II-IV) HF, an LVEF of ≥45%, elevated natriuretic peptides, and evidence of structural heart disease.[9]

Patients were randomized to receive either sacubitril/valsartan (target dose 97/103 mg twice daily) or the active comparator, valsartan (target dose 160 mg twice daily), to isolate the effect of neprilysin inhibition.[19] The primary outcome was a composite of total (first and recurrent) HF hospitalizations and CV death.[21]

After a median follow-up of 35 months, the trial narrowly missed statistical significance for its primary endpoint. The rate of primary events was 12.8 per 100 patient-years in the sacubitril/valsartan group compared to 14.6 per 100 patient-years in the valsartan group. This represented a 13% relative rate reduction that was of borderline statistical significance (Rate Ratio 0.87; 95% CI, 0.75-1.01; p=0.059).[19] The trend toward benefit was driven primarily by a non-significant 15% reduction in total HF hospitalizations (RR 0.85; 95% CI, 0.72-1.00), with little effect on CV death.[26]

3.2. A Nuanced Interpretation: Subgroup Analyses and the Spectrum of LVEF

Although the overall trial result was technically neutral, the prespecified subgroup analyses revealed a critical heterogeneity of treatment effect that held profound clinical and regulatory implications. These analyses demonstrated that the benefit of sacubitril/valsartan was not uniform across the HFpEF population but was instead concentrated in specific, identifiable patient groups.

The most important finding was the interaction between treatment effect and baseline LVEF. The benefit of sacubitril/valsartan was almost entirely confined to patients with an LVEF at or below the study's median value of 57%. In this large subgroup, sacubitril/valsartan produced a significant reduction in the primary outcome, with a magnitude of benefit remarkably similar to that observed in the HFrEF patients of the PARADIGM-HF trial.[26] Conversely, no benefit was seen in patients with higher LVEFs (Table 2).

Another striking finding was a significant interaction by sex. Women, who comprised 52% of the trial population, appeared to derive substantial benefit from sacubitril/valsartan, with a 27% reduction in the primary outcome. In contrast, men showed no evidence of benefit.[19] The biological reasons for this sex-specific difference are not fully understood but suggest fundamental differences in the pathophysiology of HFpEF between men and women, opening a vital new avenue for research.

Table 2: Key Subgroup Analyses of the Primary Outcome in PARAGON-HF (Sacubitril/Valsartan vs. Valsartan)

Subgroup	Rate Ratio (95% CI)	p-value for Interaction
Overall Population	0.87 (0.75−1.01)	N/A
LVEF ≤ 57%	0.78 (0.64−0.95)	\multirow{2}{*}{0.05}
LVEF > 57%	1.00 (0.81−1.23)
Female Sex	0.73 (0.59−0.90)	\multirow{2}{*}{0.017}
Male Sex	1.03 (0.84−1.25)
(Data sourced from 19)

While the primary endpoint was missed, sacubitril/valsartan did demonstrate statistically significant benefits in key secondary outcomes. Patients in the sacubitril/valsartan group were more likely to experience an improvement in NYHA functional class and had a significantly lower risk of the renal composite outcome (a 50% reduction in risk of end-stage renal disease, death from renal failure, or a >50% decline in eGFR) compared to those on valsartan alone.[19]

3.3. The Expanded Indication: Clinical Implications for Patients Across the Ejection Fraction Spectrum

The nuanced results of PARAGON-HF, particularly the robust evidence of benefit in the large subgroup of patients with LVEF below normal, prompted a re-evaluation of the traditional, rigid definitions of heart failure based on LVEF cutoffs. The data strongly suggested that the pathophysiology of heart failure is a biological continuum, and that the mechanisms targeted by ARNI therapy in HFrEF remain relevant and treatable in patients with LVEFs extending into the lower range of the preserved spectrum (often termed HF with mildly reduced ejection fraction, or HFmrEF).

Recognizing this, the U.S. Food and Drug Administration (FDA), in a landmark decision in February 2021, granted an expanded indication for sacubitril/valsartan.[9] The new indication is "to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure," with the crucial qualifier that "Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal".[9] The label further empowers clinicians by stating, "LVEF is a variable measure, so use clinical judgment in deciding whom to treat".[29] This novel, flexible indication effectively created a new, broad category of treatable heart failure, providing the first approved therapy with proven benefit for many patients who previously had no evidence-based treatment options.[9]

Section 4: Guideline-Directed Medical Therapy and Regulatory Status

The journey of sacubitril/valsartan from a novel investigational compound to a foundational element of heart failure care has been marked by a series of key regulatory approvals and an unprecedentedly rapid integration into global clinical practice guidelines.

4.1. FDA-Approved Indications for Adult and Pediatric Populations

The regulatory history of sacubitril/valsartan in the United States reflects its expanding evidence base:

• Initial Approval (July 7, 2015): The FDA first approved Entresto for the treatment of patients with chronic HFrEF (NYHA Class II-IV) to reduce the risk of CV death and HF hospitalization, based on the strength of the PARADIGM-HF trial results.[11]
• Pediatric Approval (October 1, 2019): The indication was expanded to include the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.[30]
• Expanded Adult Indication (February 16, 2021): Following review of the PARAGON-HF data, the FDA granted the broad indication for chronic heart failure in adults, noting that benefits are most evident in those with LVEF below normal. This made it the first therapy approved for a wide range of patients across the ejection fraction spectrum, including many with HFpEF.[9]
• New Formulation Approval (April 12, 2024): The FDA approved Entresto Sprinkle, a formulation of oral pellets within capsules, to facilitate administration in pediatric patients and adults who are unable to swallow tablets.[16]

4.2. Integration into Clinical Practice Guidelines (ACC/AHA/HFSA)

The response from major cardiology societies to the PARADIGM-HF data was swift and decisive, reflecting the unambiguous and large-magnitude benefit demonstrated. For decades, ACE inhibitors had been the undisputed cornerstone of HFrEF therapy, and displacing such an entrenched standard requires exceptionally strong evidence. The 20% reduction in CV death and 16% reduction in all-cause mortality provided by sacubitril/valsartan over and above an ACE inhibitor constituted such evidence.[10]

This led to a rapid evolution of clinical practice guidelines:

• 2016 Focused Update: The American College of Cardiology (ACC), American Heart Association (AHA), and Heart Failure Society of America (HFSA) issued a focused update recommending that ARNI therapy be considered to replace ACE inhibitor or ARB therapy in eligible patients with chronic symptomatic HFrEF.[2]
• 2017/2022 Guideline Updates: In subsequent comprehensive guideline updates, the recommendation was strengthened significantly. Sacubitril/valsartan received a Class 1 (strongest) recommendation for patients with chronic symptomatic (NYHA Class II or III) HFrEF. The guidelines now state that an ARNI is the preferred therapy over an ACE inhibitor or ARB, and that eligible patients already on an ACE inhibitor or ARB should be switched to an ARNI to further reduce morbidity and mortality.[6] This cemented its position as the new standard of care for RAAS inhibition in this population.

4.3. Sacubitril/Valsartan as a Foundational Pillar of HFrEF Therapy

The establishment of ARNI therapy as a Class 1 recommendation coincided with a broader shift in the philosophy of HFrEF management. The previous paradigm often involved a sequential, step-wise addition of medications. Current guidelines now advocate for a more aggressive, comprehensive approach centered on rapid, simultaneous initiation of four classes of medications with proven mortality benefits, often referred to as "quadruple therapy" or the "four pillars" of Guideline-Directed Medical Therapy (GDMT).[6]

The four foundational pillars of modern HFrEF therapy are [6]:

1. Angiotensin Receptor-Neprilysin Inhibitor (ARNI): Sacubitril/valsartan.
2. Evidence-Based Beta-Blocker: (e.g., metoprolol succinate, carvedilol, bisoprolol).
3. Mineralocorticoid Receptor Antagonist (MRA): (e.g., spironolactone, eplerenone).
4. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: (e.g., dapagliflozin, empagliflozin).

This modern strategy emphasizes initiating all four drug classes as early as possible and titrating them to maximally tolerated doses to achieve the greatest and most rapid reduction in mortality and morbidity.[6]

Section 5: Practical Guidance on Dosing and Administration

The safe and effective implementation of sacubitril/valsartan in clinical practice requires a thorough understanding of its available formulations, dosing protocols, titration schedules, and critical procedures for switching from other RAAS inhibitors.

5.1. Formulations and Dosage Strengths

Sacubitril/valsartan is available in several formulations to accommodate a range of patient needs [1]:

• Film-Coated Tablets: This is the standard formulation for adults and older children. Tablets are available in three strengths, with the dosage expressed as the amount of sacubitril followed by the amount of valsartan [1]:
• 24 mg / 26 mg
• 49 mg / 51 mg
• 97 mg / 103 mg
• Entresto Sprinkle (Oral Pellets): This formulation is designed for pediatric patients and adults who have difficulty swallowing tablets. It consists of hard gelatin capsules containing oral pellets. The capsules must be opened and the entire contents sprinkled onto a small amount of soft food (e.g., applesauce, yogurt) and consumed immediately. The empty capsule shell should not be swallowed, and the pellets should not be chewed or crushed.[16] Available strengths are [16]:
• 6 mg / 6 mg
• 15 mg / 16 mg
• Oral Suspension: For patients who require a liquid formulation, a pharmacist can compound an oral suspension from the 49/51 mg tablets. The standard concentration prepared is 4 mg/mL (1.96 mg/mL sacubitril and 2.04 mg/mL valsartan).[30]

5.2. Dosing Regimens and Titration Schedules

Dosing is highly individualized based on age, weight (for pediatrics), prior medication history, and renal/hepatic function.

Table 3: Adult Dosing and Titration Protocol

Patient's Prior RAAS Inhibitor Status	Action Required Before Starting	Recommended Starting Dose (twice daily)	Titration Schedule	Target Maintenance Dose (twice daily)
On high-dose ACEi (e.g., >10 mg enalapril)	STOP ACEi. Wait 36 hours (mandatory washout).	49 mg / 51 mg	Double dose every 2-4 weeks as tolerated.	97 mg / 103 mg
On high-dose ARB (e.g., >160 mg valsartan)	STOP ARB. No washout needed.	49 mg / 51 mg	Double dose every 2-4 weeks as tolerated.	97 mg / 103 mg
On low-dose ACEi (e.g., ≤10 mg enalapril)	STOP ACEi. Wait 36 hours (mandatory washout).	24 mg / 26 mg	Double dose every 2-4 weeks as tolerated.	97 mg / 103 mg
On low-dose ARB or No prior RAAS inhibitor	STOP ARB. No washout needed.	24 mg / 26 mg	Double dose every 2-4 weeks as tolerated.	97 mg / 103 mg
(Data sourced from 1)

Table 4: Pediatric Weight-Based Dosing and Titration (Twice Daily)

Patient Weight (kg)	Recommended Formulation	Starting Dose	Second Dose (after 2 wks)	Final/Target Dose (after 2 wks)
< 13 kg	Oral Suspension	1.6 mg/kg	2.3 mg/kg	3.1 mg/kg
13 to < 19 kg	Oral Pellets	12 mg / 12 mg	18 mg / 18 mg	24 mg / 24 mg
19 to < 26 kg	Oral Pellets	18 mg / 18 mg	24 mg / 24 mg	30 mg / 32 mg
26 to < 34 kg	Oral Pellets	24 mg / 24 mg	30 mg / 32 mg	45 mg / 48 mg
34 to < 40 kg	Oral Pellets	30 mg / 32 mg	45 mg / 48 mg	60 mg / 64 mg
40 to < 50 kg	Tablets	24 mg / 26 mg	49 mg / 51 mg	72 mg / 78 mg
≥ 50 kg	Tablets	49 mg / 51 mg	72 mg / 78 mg	97 mg / 103 mg
(Data sourced from 30)

5.3. Critical Protocols for Switching from ACE Inhibitors and ARBs

The procedure for switching patients to sacubitril/valsartan is a critical safety checkpoint and differs significantly depending on the prior medication.

• Switching from an ACE Inhibitor: A mandatory 36-hour washout period must be observed.[1] The ACE inhibitor must be discontinued, and the first dose of sacubitril/valsartan must not be administered until at least 36 hours have passed. This protocol is essential to allow the effects of the ACE inhibitor on bradykinin metabolism to dissipate, thereby minimizing the risk of life-threatening angioedema that could result from the concomitant effects of ACE and neprilysin inhibition. This logistical requirement is a significant implementation hurdle and a primary source of potential medication errors, demanding clear patient and provider education.
• Switching from an ARB: No washout period is required.[1] The ARB is simply discontinued, and the first dose of sacubitril/valsartan can be started at the time the next dose of the ARB would have been due. This simpler process reflects the fact that ARBs do not significantly impact bradykinin levels.

5.4. Dose Adjustments in Special Populations

Dose adjustments are required for patients with significant renal or hepatic impairment to account for altered drug clearance and increased risk of adverse effects.

• Renal Impairment:
• Severe (eGFR < 30 mL/min/1.73 m²): The recommended starting dose should be halved. For adults, this is 24 mg/26 mg twice daily.[1] For pediatric patients in this category, specific guidance should be followed, which may involve starting at 0.8 mg/kg twice daily using a liquid or pellet formulation.[16]
• Mild to Moderate (eGFR 30-90 mL/min/1.73 m²): No initial dose adjustment is required, but renal function should be monitored closely.[17]
• Hepatic Impairment:
• Moderate (Child-Pugh Class B): The recommended starting dose should be halved (e.g., 24 mg/26 mg twice daily for adults).[1]
• Mild (Child-Pugh Class A): No starting dose adjustment is necessary.[17]
• Severe (Child-Pugh Class C): Use is not recommended due to a lack of clinical data and potential for significant drug accumulation.[33]
• Hypotension: For patients with a systolic blood pressure (SBP) that is low but acceptable for initiation (i.e., ≥100 mmHg but <110 mmHg), it is prudent to consider initiating therapy at the lower starting dose of 24 mg/26 mg twice daily, even if their prior RAAS inhibitor dose was high.[37]

Section 6: Comprehensive Safety Profile and Risk Management

The safety profile of sacubitril/valsartan is well-characterized and is a direct and predictable reflection of its dual mechanism of action. Proactive monitoring and an understanding of its contraindications and potential interactions are essential for safe prescribing.

6.1. Adverse Drug Reactions: Common and Clinically Significant

The most frequently reported adverse reactions in clinical trials are hypotension, hyperkalemia, cough, dizziness, and renal impairment.[1] The PARADIGM-HF trial provides high-quality comparative data on the incidence of these events versus the previous standard of care, enalapril. This comparison reveals a nuanced safety profile: while sacubitril/valsartan is associated with a higher rate of symptomatic hypotension, it causes significantly less cough and hyperkalemia than enalapril.

Table 5: Incidence of Key Adverse Events in PARADIGM-HF (Sacubitril/Valsartan vs. Enalapril)

Adverse Event	Sacubitril/Valsartan (Incidence %)	Enalapril (Incidence %)	Commentary / p-value
Symptomatic Hypotension	14.0%	9.2%	p < 0.001 23
Hyperkalemia (K+ > 5.5 mmol/L)	16.1%	17.3%	p = 0.15 23
Cough	11.3%	14.3%	p < 0.001 23
Serum Creatinine Increase ≥ 2.5 mg/dL	3.3%	4.5%	p = 0.007 23
Angioedema	0.5%	0.2%	Not statistically significant, but numerically higher 17
(Data sourced from 10)

6.2. Warnings and Precautions

The prescribing information for sacubitril/valsartan includes several critical warnings and precautions that guide its safe use.

6.2.1. Fetal Toxicity (Boxed Warning)

Sacubitril/valsartan carries a boxed warning for fetal toxicity.[30] Like all drugs that act directly on the RAAS, it can cause significant fetal injury (including renal failure, lung hypoplasia, and skeletal deformations) and death when administered during the second and third trimesters of pregnancy.[30] The medication is absolutely contraindicated in pregnancy and must be discontinued immediately if a patient becomes pregnant.[34]

6.2.2. Angioedema: Risk Factors and Management

Angioedema, characterized by swelling of the deep tissues of the face, lips, tongue, or throat, is a rare but potentially life-threatening adverse reaction.[34] If angioedema occurs, sacubitril/valsartan must be discontinued immediately and permanently, and the patient must be provided with appropriate therapy, including emergency management for airway compromise if necessary.[1] The risk of angioedema is known to be higher in Black patients and in individuals with a prior history of angioedema from any cause.[16] The drug is contraindicated in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy, as well as in those with hereditary angioedema.[11]

6.2.3. Hypotension, Renal Impairment, and Hyperkalemia

These three adverse events are the most common and are direct pharmacological consequences of the drug's mechanism.

• Hypotension: The potent vasodilatory effects of the drug can lead to symptomatic hypotension, particularly in patients who are volume- or salt-depleted (e.g., those on high-dose diuretics) or at the initiation of therapy.[34] Blood pressure must be monitored at baseline and with each dose increase. If symptomatic hypotension occurs, dose reduction or temporary discontinuation may be necessary.[1]
• Renal Impairment: By altering renal hemodynamics, the drug can cause increases in serum creatinine and, rarely, acute renal failure.[34] Renal function (serum creatinine and eGFR) must be monitored at baseline, one week after initiation or any dose increase, and periodically during stable maintenance therapy.[1]
• Hyperkalemia: By suppressing aldosterone, the drug reduces potassium excretion, which can lead to hyperkalemia.[34] The risk is increased in patients with underlying renal impairment, diabetes, or those taking other medications that raise potassium levels. Serum potassium must be monitored on the same schedule as renal function.[1]

6.3. Contraindications and Significant Drug-Drug Interactions

In addition to pregnancy and a history of angioedema, there are several other absolute contraindications and clinically significant drug interactions.

Contraindications Summary:

1. Hypersensitivity: Known hypersensitivity to sacubitril, valsartan, or any excipients.[5]
2. History of Angioedema: History of angioedema related to prior ACE inhibitor or ARB therapy, or hereditary angioedema.[11]
3. Concomitant ACE Inhibitor Use: Co-administration with an ACE inhibitor is strictly contraindicated. The mandatory 36-hour washout period must be respected.[1]
4. Concomitant Aliskiren Use: Co-administration with the direct renin inhibitor aliskiren is contraindicated in patients with diabetes.[11]

Significant Drug-Drug Interactions:

• Dual RAAS Blockade: Sacubitril/valsartan should not be used with an ACE inhibitor or another ARB, as this constitutes dual RAAS blockade and increases the risk of adverse events like hypotension, hyperkalemia, and renal impairment.[1]
• Potassium-Sparing Diuretics and Supplements: Concomitant use with agents like spironolactone, eplerenone, amiloride, or potassium supplements increases the risk of severe hyperkalemia and requires careful monitoring.[11]
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): In patients who are elderly, volume-depleted, or have compromised renal function, co-administration of NSAIDs (including selective COX-2 inhibitors) can lead to a worsening of renal function and potentially acute renal failure.[11]
• Lithium: Co-administration can decrease the renal clearance of lithium, leading to an increased risk of lithium toxicity. Serum lithium levels should be monitored closely.[11]
• OATP1B1/OATP1B3 Transporter Inhibitors: Sacubitril/valsartan is a substrate of these transporters. Concomitant use with inhibitors (e.g., certain statins like atorvastatin, cyclosporine, rifampin) may increase the systemic exposure of sacubitril/valsartan. Caution is advised, particularly with statins, where increased monitoring for statin-related toxicity may be warranted.[14]

Section 7: Synthesis and Future Perspectives

7.1. Summary of the Therapeutic Role of Sacubitril/Valsartan

Sacubitril/valsartan has fundamentally transformed the management of chronic heart failure. For patients with HFrEF, it is no longer an alternative therapy but a foundational, Class 1 recommended standard of care. The evidence from the PARADIGM-HF trial is unequivocal, demonstrating a substantial and clinically meaningful reduction in cardiovascular mortality, all-cause mortality, and heart failure hospitalizations compared to the previous cornerstone of therapy, an ACE inhibitor. Its integration as one of the four essential pillars of GDMT underscores its critical role in improving survival and quality of life in this population.

For patients with HFpEF, a condition historically bereft of effective treatments, sacubitril/valsartan has opened a new therapeutic frontier. While the PARAGON-HF trial did not meet its primary endpoint in the overall population, its nuanced results provided the first robust evidence of benefit for a pharmacological agent in a large segment of these patients—specifically, those with LVEF in the lower-preserved range and women. This led to a landmark expanded FDA indication that moves beyond rigid LVEF cutoffs, empowering clinical judgment and providing a much-needed treatment option for millions of patients across the heart failure spectrum.

7.2. Unresolved Questions and Areas for Future Research

Despite its established success, several important questions regarding sacubitril/valsartan remain, representing key areas for future investigation:

• Long-Term Cognitive Effects: The theoretical risk of promoting Alzheimer's disease via impaired amyloid-beta clearance remains a topic of scientific interest. Although short- to medium-term data are reassuring, long-term prospective studies with dedicated cognitive endpoints are needed to definitively address this concern.[2]
• Understanding HFpEF Phenotypes: The sex-specific benefit and the LVEF-dependent efficacy observed in PARAGON-HF highlight the heterogeneity of HFpEF. Future research must focus on elucidating the underlying pathophysiological differences between these patient subgroups to better target therapies and to understand why ARNI therapy is effective in some phenotypes but not others.
• Implementation Science: Significant gaps persist between guideline recommendations and real-world clinical practice. Many eligible patients are not prescribed sacubitril/valsartan, and many who are do not reach target doses.[22] Research into implementation science is crucial to identify and overcome barriers—such as cost, clinician inertia, the complexity of the washout period, and management of side effects—to ensure that this life-saving therapy reaches all patients who stand to benefit.
• Expansion to Other Indications: The pleiotropic cardioprotective effects of sacubitril/valsartan suggest potential benefits in other cardiovascular conditions. Ongoing and future trials will explore its role in settings such as post-myocardial infarction remodeling, hypertension without heart failure, and chronic kidney disease.

7.3. Concluding Remarks on the Impact of ARNI Therapy

The development and clinical validation of sacubitril/valsartan represent a triumph of translational medicine. It is a case study in how a deep understanding of complex pathophysiology—the neurohormonal imbalance in heart failure—can lead to the rational design of a targeted molecule. The ARNI class was born from the lessons of past failures, intelligently designed to maximize therapeutic benefit while minimizing risk. The subsequent execution of a landmark clinical trial, PARADIGM-HF, provided definitive proof of its life-saving efficacy, leading to a rapid and justified reshaping of the global standard of care. By simultaneously augmenting the body's protective mechanisms and suppressing its harmful ones, sacubitril/valsartan has provided a powerful new tool to alter the natural history of heart failure, offering patients longer lives with fewer hospitalizations. Its impact on cardiovascular medicine will be felt for decades to come.

Works cited

1. Sacubitril with Valsartan (Entresto) for Heart Failure with reduced ejection fraction Fact Sheet - Queensland Health, accessed July 22, 2025, https://www.health.qld.gov.au/__data/assets/pdf_file/0028/675127/Sacubitril_w_Valsartan_fact_sheet.pdf
2. Sacubitril/valsartan - Wikipedia, accessed July 22, 2025, https://en.wikipedia.org/wiki/Sacubitril/valsartan
3. The history and mystery of sacubitril/valsartan: From ... - Frontiers, accessed July 22, 2025, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1102521/full
4. PARADIGM-HF: Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in HF - American College of Cardiology, accessed July 22, 2025, https://www.acc.org/Latest-in-Cardiology/Articles/2015/02/09/10/19/PARADIGM-HF-Prospective-Comparison-of-ARNI-With-ACEI
5. Sacubitril-Valsartan - StatPearls - NCBI Bookshelf, accessed July 22, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507904/
6. Heart failure with reduced ejection fraction: What's new in the 2022 ..., accessed July 22, 2025, https://www.ccjm.org/content/ccjom/90/4/215.full.pdf
7. Critical Questions about PARADIGM-HF and the Future - PMC, accessed July 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4963414/
8. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review, accessed July 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8631913/
9. Novartis Entresto® granted expanded indication in chronic heart failure by FDA, accessed July 22, 2025, https://www.novartis.com/news/media-releases/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda
10. Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial, accessed July 22, 2025, https://www.novartis.com/us-en/news/media-releases/novartis-new-heart-failure-medicine-lcz696-cut-cardiovascular-deaths-20-vs-ace-inhibitor-landmark-paradigm-hf-trial
11. Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure, accessed July 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4636283/
12. Sacubitril: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 22, 2025, https://go.drugbank.com/drugs/DB09292
13. Entresto (sacubitril / valsartan): Uses, Side Effects, Dosage & More - GoodRx, accessed July 22, 2025, https://www.goodrx.com/entresto/what-is
14. Sacubitril/valsartan (ENTRESTO™) - Cardiac Services BC, accessed July 22, 2025, http://www.cardiacbc.ca/Documents/ARNI-Summary-resource%20and%20Practical%20tips.pdf
15. Molecular mechanisms of sacubitril/valsartan in cardiac remodeling - Frontiers, accessed July 22, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.892460/full
16. TX HHSC New Drug Update, accessed July 22, 2025, https://www.hhs.texas.gov/sites/default/files/documents/october-2024-durb-agenda-item4f.pdf
17. 1 Trade name - Novartis, accessed July 22, 2025, https://www.novartis.com/sg-en/sites/novartis_sg/files/Entresto-Jun2020.SINv2-app101022-pdf.pdf
18. Heart Failure Guidelines: Introduction to the New Agents - U.S. Pharmacist, accessed July 22, 2025, https://www.uspharmacist.com/article/heart-failure-guidelines-introduction-to-the-new-agents
19. Prospective Comparison of ARNI With ARB Global Outcomes in HF ..., accessed July 22, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2019/08/30/21/24/PARAGON-HF
20. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy, accessed July 22, 2025, https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.116.003212
21. Clinical Trial and Biomarker Data | ENTRESTO® (sacubitril/valsartan) | HCP, accessed July 22, 2025, https://www.entrestohcp.com/hfref/clinical-trial-biomarker-data
22. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction | JACC, accessed July 22, 2025, https://www.jacc.org/doi/10.1016/j.jacc.2022.08.737
23. Prospective Comparison of ARNI With ACEI to Determine Impact on ..., accessed July 22, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2014/08/30/12/22/PARADIGM-HF
24. Practical guidance on the use of sacubitril/valsartan for heart failure - PMC, accessed July 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6394573/
25. Sacubitril/Valsartan for Worsening Heart Failure - American College of Cardiology, accessed July 22, 2025, https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2024/03/20/16/13/sacubitril-valsartan-in-patients
26. PARAGON-HF Trial Overview - American Journal of Managed Care, accessed July 22, 2025, https://www.ajmc.com/view/paragon-hf-trial-overview
27. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF) - ClinicalTrials.gov, accessed July 22, 2025, https://clinicaltrials.gov/study/NCT01920711
28. PARAGON-HF - Wiki Journal Club, accessed July 22, 2025, https://www.wikijournalclub.org/wiki/PARAGON-HF
29. Novartis Entresto® granted expanded indication in chronic heart failure by FDA | HFSA, accessed July 22, 2025, https://hfsa.org/novartis-entrestor-granted-expanded-indication-chronic-heart-failure-fda
30. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ..., accessed July 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/207620s025,218591s000lbl.pdf
31. FDA Approves New Heart Failure Drug - American College of Cardiology, accessed July 22, 2025, https://www.acc.org/latest-in-cardiology/articles/2015/07/08/10/00/fda-approves-new-heart-failure-drug
32. Entresto (sacubitril and valsartan) FDA Approval History - Drugs.com, accessed July 22, 2025, https://www.drugs.com/history/entresto.html
33. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial - PubMed Central, accessed July 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7286640/
34. Entresto (sacubitril/valsartan): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed July 22, 2025, https://www.webmd.com/drugs/2/drug-169241/entresto-oral/details
35. Entresto Dosage Guide - Drugs.com, accessed July 22, 2025, https://www.drugs.com/dosage/entresto.html
36. Sacubitril and valsartan (oral route) - Side effects & dosage - Mayo Clinic, accessed July 22, 2025, https://www.mayoclinic.org/drugs-supplements/sacubitril-and-valsartan-oral-route/description/drg-20150920
37. Entresto, INN-sacubitril/valsartan - EMA, accessed July 22, 2025, https://www.ema.europa.eu/en/documents/product-information/entresto-epar-product-information_en.pdf
38. HIGHLIGHTS OF PRESCRIBING INFORMATION These ... - Novartis, accessed July 22, 2025, https://www.novartis.com/us-en/sites/novartis_us/files/entresto.pdf
39. Dosing & Titration | ENTRESTO® (sacubitril/valsartan) | HCP, accessed July 22, 2025, https://www.entrestohcp.com/safety-and-dosing/dosing
40. 5 Entresto Side Effects to Know and How to Manage Them - GoodRx, accessed July 22, 2025, https://www.goodrx.com/entresto/entresto-side-effects-you-should-know-about
41. Sacubitril / Valsartan Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 22, 2025, https://www.drugs.com/sfx/sacubitril-valsartan-side-effects.html
42. Sacubitril/valsartan (Entresto®) - Together by St. Jude™, accessed July 22, 2025, https://together.stjude.org/en-us/treatment-tests-procedures/medicines-list/sacubitril-valsartan-entresto.html
43. Entresto (sacubitril/valsartan) dosing, indications, interactions, adverse effects, and more, accessed July 22, 2025, https://reference.medscape.com/drug/entresto-sacubitril-valsartan-1000010